Diverging Relative Clinical Benefit Assessment Across HAS and G-BA: A Forecast for EU HTA in Oncology Drugs.

This analysis highlights critical variations in clinical benefit assessments between key European HTA bodies, with a focus on oncology therapeutics. The presentation offers a forward-looking perspective on how these differences may shape the trajectory of EU HTA harmonisation.

Presented at ISPOR EU 2023, Barcelona, Spain.

Please click here to download the poster. Don’t forget to subscribe to our newsletter below for the latest company updates, recently published HTA guidance, industry insights, and more!

‍